Osteopenia and osteoporosis: Previously unrecognized manifestations of Fabry disease [3]

Clinical Genetics

Volumn 68, Issue 1, 2005, Pages 93-95

  Germain, Dominique P ^a   Benistan, Karelle ^a   Boutouyrie, Pierre ^a   Mutschler, Céline ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; CARBAMAZEPINE;

ADOLESCENT; ADULT; BODY MASS; BONE DENSITY; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; ENZYME REPLACEMENT; FABRY DISEASE; FRAGILITY FRACTURE; HUMAN; LETTER; MALE; NEUROPATHIC PAIN; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BODY WEIGHT; BONE DENSITY; BONE DISEASES; FABRY DISEASE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 20944449722     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2005.00457.x     Document Type: Letter

References (8)

1. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003: 138: 338-346.
2. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994: 4: 368-381.
3. Cellier C, Flobert C, Cormier C, Roux C, Schmitz J. Severe osteopenia in symptom-free adults with a childhood diagnosis of coeliac disease. Lancet 2000: 355: 806.
4. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Arterial remodelling in Fabry disease. Acta Paediatr Suppl 2002: 91: 62-66.
5. Cizza G, Ravn P, Chrousos GP, Gold PW. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 2001: 12: 198-203.
6. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002: 58: 1348-1353.
7. Horiuchi H, Saito N, Kobayashi S, Ota H, Taketomi T, Takaoka K. Avascular necrosis of the femoral head in a patient with Fabry's disease: identification of ceramide trihexoside in the bone by delayed-extraction matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum 2002: 46: 1922-1925.
8. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry's Disease. Am J Hum Genet 2004: 75: 65-74.